Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Purchase Disclosed by Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros Jr. purchased $1,001–$15,000 of Ultragenyx Pharmaceutical stock on September 29, according to a congressional disclosure.
• Ultragenyx reported better-than-expected quarterly results, with a loss of $0.90 per share versus analysts’ expected loss of $1.22 and revenue of $214 million, up 28.5% year over year.
• RARE shares opened at $14.92, near their 52-week low, while analysts have largely turned cautious: the stock carries a consensus “Hold” rating and an average price target of $34.58.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ultragenyx Pharmaceutical stock on September 29th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Sold $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Sold $1,001 - $15,000 in shares of AtriCure NASDAQ: ATRC on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Alkermes NASDAQ: ALKS on 9/29/2026.

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $14.92 on Wednesday. The business has a 50 day moving average price of $19.46 and a 200 day moving average price of $23.68. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $12.73 and a fifty-two week high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping analysts' consensus estimates of ($1.22) by $0.32. The company had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. During the same period in the previous year, the business posted ($1.17) EPS. The firm's revenue for the quarter was up 28.5% compared to the same quarter last year. Analysts forecast that Ultragenyx Pharmaceutical Inc. will post -3.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several institutional investors have recently made changes to their positions in RARE. BlackRock Inc. purchased a new stake in Ultragenyx Pharmaceutical during the second quarter worth about $355,746,000. Assenagon Asset Management S.A. lifted its position in shares of Ultragenyx Pharmaceutical by 1,030.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company's stock valued at $47,298,000 after acquiring an additional 2,057,951 shares during the period. Bank of America Corp DE acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at approximately $38,347,000. Jefferies Financial Group Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $31,040,000. Finally, Eagle Health Investments LP purchased a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $29,521,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on RARE. Weiss Ratings reiterated a "sell (d-)" rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, October 6th. The Goldman Sachs Group lowered their target price on shares of Ultragenyx Pharmaceutical from $28.00 to $19.00 and set a "neutral" rating on the stock in a research report on Friday, September 4th. Evercore lowered shares of Ultragenyx Pharmaceutical from an "outperform" rating to an "in-line" rating and set a $16.00 target price on the stock. in a research report on Thursday, September 3rd. Wedbush cut their target price on shares of Ultragenyx Pharmaceutical from $30.00 to $23.00 and set a "neutral" rating on the stock in a report on Thursday, September 3rd. Finally, Wells Fargo & Company downgraded shares of Ultragenyx Pharmaceutical from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $50.00 to $18.00 in a research report on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of "Hold" and an average price target of $34.58.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. The company targets conditions with limited or no treatment options, including metabolic disorders, skeletal diseases and other inherited conditions. Its work includes the development of medicines, biologic therapies and gene therapy candidates intended to address the underlying causes or significant symptoms of these disorders.

Ultragenyx's commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Dojolvi (triheptanoin), a medical food used to manage long-chain fatty acid oxidation disorders; and Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.